Day: January 15, 2026

Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presence Next-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipeline Multiple global registrational Phase III trials are progressing rapidlyROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its Chairman and CEO, Dajun Yang, M.D., Ph.D., presented at the 44th Annual J.P. Morgan Healthcare Conference. In the corporate presentation, Dr....

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company’s issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a special resolution authorizing the Board of Directors, at any time prior to the next annual meeting of shareholders, to implement a share consolidation at a ratio of up to 1-for-50, with the exact timing and consolidation ratio to be determined in the Board’s sole discretion. Following this approval, the Company’s Board of Directors initially authorized a 1-for-7.97 consolidation ratio which was implemented Monday, May 5, 2025. On December 4, 2025, the board approved a...

MONTREAL, Jan. 14, 2026 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) today announced that two long-standing members of its Board of Directors, Robert Taub, Chair of the Board, and Dr. Jürgen Hambrecht, Lead Independent Director, will not stand for re-election at the Corporation’s upcoming annual meeting, and will retire from the Board at the conclusion of their current terms. Robert Taub has served on the Board for 10 years, including as Chair since 2020. As a founding member with a significant stake since the inception of the business, he has played a pivotal role in Aya’s evolution and successful turnaround over the past five years, providing strategic leadership guided by innovation and an entrepreneurial mindset. Dr. Jürgen Hambrecht has served on the Board since 2019...